Empagliflozin safe in acute HF, improves 'Clinical Benefit' over time
Patients with acute heart failure were safely started on empagliflozin a median of 3 days after hospitalization and were 36% more likely to "experience a clinical benefit" over the next 90 days compared with patients taking a placebo, the EMPULSE trial highlights. The benefits of empagliflozin in this very early acute setting, included better survival, fewer hospitalizations, and...
Patients with acute heart failure were safely started on empagliflozin a median of 3 days after hospitalization and were 36% more likely to "experience a clinical benefit" over the next 90 days compared with patients taking a placebo, the EMPULSE trial highlights.
The benefits of empagliflozin in this very early acute setting, included better survival, fewer hospitalizations, and greater improvements quality of life (QoL)—all of which made up the primary composite endpoint in this study
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd